Sanofi Biotechnology SAS Sustainability Profile
Sanofi Biotechnology SAS, a prominent player in the biopharmaceutical industry, is headquartered in France and operates extensively across Europe, North America, and Asia. Founded in 2004, the company has established itself as a leader in biotechnology, focusing on innovative therapies for various diseases, including rare and chronic conditions. Sanofi Biotechnology is renowned for its cutting-edge biologics and biosimilars, which are distinguished by their high quality and efficacy. The company’s commitment to research and development has led to significant milestones, including advancements in monoclonal antibodies and gene therapies. With a strong market position, Sanofi Biotechnology continues to achieve notable successes, contributing to the global healthcare landscape and improving patient outcomes worldwide.
DitchCarbon Score
How does Sanofi Biotechnology SAS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sanofi Biotechnology SAS's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sanofi Biotechnology SAS, headquartered in France, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Sanofi, which has established various climate commitments and initiatives aimed at reducing carbon emissions across its operations. Sanofi has set science-based targets (SBTi) to guide its emissions reduction efforts, which are cascaded down to Sanofi Biotechnology SAS. These targets are part of a broader commitment to sustainability and climate action within the corporate family. Additionally, Sanofi participates in initiatives such as the Carbon Disclosure Project (CDP) and RE100, which further emphasise its dedication to transparency and renewable energy usage. While specific reduction targets or achievements for Sanofi Biotechnology SAS are not detailed, the overarching goals from the parent company indicate a commitment to addressing climate change and reducing environmental impact. The absence of direct emissions data highlights the need for ongoing monitoring and reporting to align with industry standards and stakeholder expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Sanofi Biotechnology SAS's Industry?
How Carbon Intensive is Sanofi Biotechnology SAS's Location?
Sanofi Biotechnology SAS's Scope 3 Categories Breakdown
Sanofi Biotechnology SAS's Scope 3 emissions, which decreased by 5% last year and increased by approximately 40% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Sanofi Biotechnology SAS's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sanofi Biotechnology SAS has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
